Patents Assigned to Pharmacia AS
-
Patent number: 9056136Abstract: The present invention incorporates weakly basic substituents (pKa about 8 or greater) such as pyrrolidine, piperidine, piperazine and azapane moieties in halogenated 2-nitromidazoles for the non-invasive detection of cellular hypoxia in normal and malignant tissues. The compounds of the invention can be used in 18F positron emission tomography, 19F magnetic resonance spectroscopy, and 19F magnetic resonance imaging.Type: GrantFiled: October 6, 2006Date of Patent: June 16, 2015Assignee: Natural Pharmacia International, Inc.Inventors: James A. Raleigh, David Y-W Lee, Xiaoshen Ji
-
Publication number: 20140141079Abstract: An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.Type: ApplicationFiled: January 28, 2014Publication date: May 22, 2014Applicant: Pharmacia CorporationInventors: Ernest J. Lee, Gerard M. Bredael, John R. Baldwin, Steven R. Cox, Mark J. Heintz
-
Patent number: 8679533Abstract: An orally deliverable pharmaceutical composition comprises a therapeutically effective amount of pramipexole or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, said composition exhibiting at least one of (a) an in vitro release profile wherein on average no more than about 20% of the pramipexole is dissolved within 2 hours after placement of the composition in a standard dissolution test; and (b) an in vivo pramipexole absorption profile following single dose administration to healthy adult humans wherein the time to reach a mean of 20% absorption is greater than about 2 hours and/or the time to reach a mean of 40% absorption is greater than about 4 hours. The composition is useful for oral administration, not more than once daily, to a subject having a condition or disorder for which a dopamine receptor agonist is indicated.Type: GrantFiled: July 24, 2003Date of Patent: March 25, 2014Assignee: Pharmacia CorporationInventors: Ernest J. Lee, Gerard M. Bredael, John R. Baldwin, Steven R. Cox, Mark J. Heintz
-
Patent number: 8518956Abstract: The present invention comprises 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts. The invention further comprises pharmaceutical compositions, methods of treatment, and synthetic methods relating to 1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)piperidine-4-carboxylic acid and its salts.Type: GrantFiled: November 17, 2010Date of Patent: August 27, 2013Assignee: Pharmacia & Upjohn Company LLCInventor: Michael B. Tollefson
-
Patent number: 8518371Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.Type: GrantFiled: November 29, 2010Date of Patent: August 27, 2013Assignee: Natural Pharmacia International, Inc.Inventors: David Y-W Lee, Xiao-Shen Ji, James A. Raleigh
-
Publication number: 20130158053Abstract: Crystalline forms of the p38 kinase inhibitor 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide is provided. Also provided are combinations and pharmaceutical compositions comprising the crystalline forms, and methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline forms.Type: ApplicationFiled: November 6, 2012Publication date: June 20, 2013Applicant: Pharmacia & Upjohn Company LLCInventor: Pharmacia & Upjohn Company LLC
-
Patent number: 8338374Abstract: The present invention is directed to stable liquid growth hormone formulations that remain stable after physical agitation, and after exposure to one or more freeze-thaw events. Formulations of the present invention can be stored long term at a variety of temperatures, even frozen. In the present invention, a combination of buffer and stabilizing agents, including a non-ionic surfactant (e.g., polysorbate 20), a polymer stabilizer (e.g., polyethylene glycol), and other optional stabilizers combine to provide unexpected stability to aqueous formulations of a growth hormone (e.g., human growth hormone).Type: GrantFiled: December 13, 2004Date of Patent: December 25, 2012Assignee: Pharmacia CorporationInventors: Manpreet S Wadhwa, Sandeep Nema, Advait Badkar
-
Publication number: 20120148625Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.Type: ApplicationFiled: June 16, 2011Publication date: June 14, 2012Applicant: PHARMACIA & UPJOHN COMPANY LLCInventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
-
Publication number: 20120015425Abstract: The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.Type: ApplicationFiled: September 29, 2011Publication date: January 19, 2012Applicant: PHARMACIA AND UP JOHN COMPANY, LLCInventors: Jay Gregory Calvert, Shelly Shields, David E. Slade, Siao-Kun Welch
-
Patent number: 8058050Abstract: The present invention provides methods and compositions related to the generation of host cells permissive for virus growth, particularly Porcine Reproductive and Respiratory Syndrome (PRRS) virus.Type: GrantFiled: May 6, 2010Date of Patent: November 15, 2011Assignee: Pharmacia and Upjohn Company LLCInventors: Jay Gregory Calvert, Shelly Shields, David E Slade, Siao-Kun Welch
-
Publication number: 20110166077Abstract: The present invention provides the use of acryloyl distamycin derivatives, in particular ?-bromo- or ?-chloro-acryloyl distamycin derivatives, in combination with radiotherapy, for the treatment of tumors.Type: ApplicationFiled: October 1, 2004Publication date: July 7, 2011Applicant: Pharmacia Italia S.p.A.Inventors: Maria Geroni, Jennifer Tursi, Camilla Fowst
-
Publication number: 20110098266Abstract: A method of administering an antibiotic to an animal in need thereof, including the step of injecting the antibiotic subcutaneously at the junction of a pinna with the cranium of the animal, is disclosed.Type: ApplicationFiled: October 27, 2010Publication date: April 28, 2011Applicant: PHARMACIA & UPJOHN COMPANY LLCInventor: Scott A. Brown
-
Publication number: 20110085975Abstract: The invention features a class of 2-nitroimidazole compounds with a secondary basic nitrogen atom and a linker bearing one or more therapeutic agents, cytotoxic agents, detectable labels, or chelating groups. In particular, the invention provides 2-nitroimidazole compounds containing a cluster of boron atoms for use in boron neutron capture therapy (BNCT). The 2-nitroimidazole compounds can be used to treat hypoxic conditions, including, e.g., cancer, inflammation, and ischemia. The weakly basic 2-nitroimidazole compounds target to hypoxic tissue and provide increased tissue concentration overall.Type: ApplicationFiled: November 29, 2010Publication date: April 14, 2011Applicant: NATURAL PHARMACIA INTERNATIONAL, INC.Inventors: David Y-W Lee, Xiao-Shen Ji, James A. Raleigh
-
Publication number: 20110059015Abstract: The application relates to antibodies and fragments capable of binding HIV-1 gp120 protein, nucleic acids encoding such proteins, to the use of such proteins to identify active compounds, and to the use of the compounds as vaccines.Type: ApplicationFiled: September 12, 2008Publication date: March 10, 2011Applicants: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS/ CSIC, PHARMACIA SPAINInventors: José Luis Toran Garcia, Carlos Martinez Alonso
-
Patent number: 7902195Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I: wherein R2, R6A, R6B and R8 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, synthetic methods, and intermediates are also disclosed.Type: GrantFiled: April 20, 2007Date of Patent: March 8, 2011Assignee: Pharmacia & Upjohn Company LLCInventors: Robert O Hughes, Andrew Simon Bell, David Graham Brown, Dafydd Owen, Michael John Palmer, Christopher Phillips, David L. Brown, Yvette M. Fobian, John N. Freskos, Steven E. Heasley, E. Jon Jacobsen, Todd Maddux, Brent Mischke, John M. Molyneaux, Joseph B. Moon, D. Joseph Rogier, Jr., Michael B. Tollefson, John K. Walker
-
Patent number: 7897151Abstract: The present invention provides compositions and methods for the use of antigenic peptides derived from the Fc portion of the epsilon heavy chain of an IgE molecule as vaccines for the treatment and prevention of IgE-mediated allergic disorders. In particular, the invention provides compositions, methods for the treatment and prevention of IgE-mediated allergic disorders comprising an immunogenic amount of one or more antigenic peptides derived from the CH3 domain or junction of Ch-3/CH4 domain of an IgE molecule and methods for the evaluation of IgE mediated allergies in dogs.Type: GrantFiled: August 4, 2005Date of Patent: March 1, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: Mohamad A. Morsey, Michael G. Sheppard, David W. Wheeler
-
Patent number: 7892574Abstract: Disclosed is a method of treating a non-topical infection selected from the group consisting of ear infections, skin and soft tissue infections, acne, infected wounds, bacteremia, in a useful warm blooded mammal who is in need of such treatment which comprises topical administration of a pharmaceutical formulation containing a transdermally effective amount of an Oxazolidinone.Type: GrantFiled: September 16, 2003Date of Patent: February 22, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: Charles W. Ford, Jeffrey L. Watts
-
Patent number: 7879336Abstract: The present invention relates to providing new vaccines and treatments for the diseases related to canine influenza virus. It discloses influenza viral antigens, and methods of presenting these antigens to canines, especially dogs. It relates to attenuated and killed vaccines. The present invention relates to experimentally generated canine and equine influenza viruses. invention also includes influenza A, including H3, N8, H3N8, H7N7 and viruses which contain at least one genome segment from an canine or equine influenza virus. The present invention also relates to the use of these viruses in therapeutic compositions to protect canines, dogs in particular, from diseases caused by influenza viruses.Type: GrantFiled: June 23, 2008Date of Patent: February 1, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: Shelly L. Shields, Hans A Draayer, Michael J Huether
-
Patent number: 7867972Abstract: The invention provides fusion proteins comprising an exendin-4 fused to a transferrin (Tf) via a polypeptide linker, as well as corresponding nucleic acid molecules, vectors, host cells, and pharmaceutical compositions. The invention also provides the use of the exendin-4/Tf fusion proteins for treatment of Type II diabetes, obesity, and to reduce body weight.Type: GrantFiled: July 24, 2007Date of Patent: January 11, 2011Assignee: Pharmacia & Upjohn Company, LLCInventors: David James Ballance, Christopher P. Prior, Homayoun Sadeghi, Andrew J. Turner
-
Publication number: 20100322975Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.Type: ApplicationFiled: June 16, 2010Publication date: December 23, 2010Applicant: PHARMACIA & UPJOHN COMPANY LLCInventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy